| Apria Healthcare Llc | |
| 10910n 2nd St, Machesney Park, Illinois 61115 | |
| (815) 633-7778 |
| Name | Apria Healthcare Llc |
|---|---|
| Organization Name | Apria Healthcare Llc |
| Location | 10910n 2nd St, Machesney Park, Illinois 61115 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (815) 633-7778 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Migraine is a particularly agonizing condition, much more than a simple headache, affecting 5% to 12% of the population. However, the condition is not diagnosed in many patients, forcing them to undergo severe pain for years on end. One of the causes for this widespread under-diagnosis is the lack of knowledge of the features that distinguish a migraine from a non-migraine headache.
Numerous experts and policy makers have called for hospitals to screen patients for methicillin-resistant Staphylococcus aureus (MRSA) infections and isolate anyone testing positive to prevent the spread of these so-called "Superbugs" in healthcare settings.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A survey of more than 3,000 patients age 40 and older reveals that physicians often leave information out when they present treatment plans to patients, who "hear far more from doctors about the pros than cons of medications, tests and surgeries." Often, "physicians tend to offer opinions, not options, the researchers found, and rarely mention to patients that they can decide not to do anything," according to the study, which was funded by the Foundation for Informed Medical Decision Making.
Spectrum, a health and science communications firm, announced the results of a global awareness campaign that "found" 24 percent more children identified with a rare, fatal, and rapid aging disease called Progeria. The findings are being shared at a Centers for Disease Control national conference on health communications.
› Verified 7 days ago
| NPI Number | 1487763066 |
| Organization Name | APRIA HEALTHCARE LLC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 10910 N 2nd St, Machesney Park, IL 61115 |
| Phone Number | 815-633-7778 |
News Archive
Migraine is a particularly agonizing condition, much more than a simple headache, affecting 5% to 12% of the population. However, the condition is not diagnosed in many patients, forcing them to undergo severe pain for years on end. One of the causes for this widespread under-diagnosis is the lack of knowledge of the features that distinguish a migraine from a non-migraine headache.
Numerous experts and policy makers have called for hospitals to screen patients for methicillin-resistant Staphylococcus aureus (MRSA) infections and isolate anyone testing positive to prevent the spread of these so-called "Superbugs" in healthcare settings.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A survey of more than 3,000 patients age 40 and older reveals that physicians often leave information out when they present treatment plans to patients, who "hear far more from doctors about the pros than cons of medications, tests and surgeries." Often, "physicians tend to offer opinions, not options, the researchers found, and rarely mention to patients that they can decide not to do anything," according to the study, which was funded by the Foundation for Informed Medical Decision Making.
Spectrum, a health and science communications firm, announced the results of a global awareness campaign that "found" 24 percent more children identified with a rare, fatal, and rapid aging disease called Progeria. The findings are being shared at a Centers for Disease Control national conference on health communications.
› Verified 7 days ago
News Archive
Migraine is a particularly agonizing condition, much more than a simple headache, affecting 5% to 12% of the population. However, the condition is not diagnosed in many patients, forcing them to undergo severe pain for years on end. One of the causes for this widespread under-diagnosis is the lack of knowledge of the features that distinguish a migraine from a non-migraine headache.
Numerous experts and policy makers have called for hospitals to screen patients for methicillin-resistant Staphylococcus aureus (MRSA) infections and isolate anyone testing positive to prevent the spread of these so-called "Superbugs" in healthcare settings.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A survey of more than 3,000 patients age 40 and older reveals that physicians often leave information out when they present treatment plans to patients, who "hear far more from doctors about the pros than cons of medications, tests and surgeries." Often, "physicians tend to offer opinions, not options, the researchers found, and rarely mention to patients that they can decide not to do anything," according to the study, which was funded by the Foundation for Informed Medical Decision Making.
Spectrum, a health and science communications firm, announced the results of a global awareness campaign that "found" 24 percent more children identified with a rare, fatal, and rapid aging disease called Progeria. The findings are being shared at a Centers for Disease Control national conference on health communications.
› Verified 7 days ago
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10910n 2nd St, Machesney Park, Illinois 61115 Phone: (815) 633-7778 | |
Mercyhealth Visiting Nurses Associa Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9934 N. Alpine Road - Suite 110, Machesney Park, Illinois 61115 Phone: (815) 971-3330 | |
Cvs Pharmacy #08528 Type: Pharmacy Location: 8001 N 2nd St, Machesney Park, Illinois 61115 Phone: (815) 636-2949 | |
Cvs Pharmacy #16922 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9833 N Alpine Rd, Machesney Park, Illinois 61115 Phone: (815) 639-3301 | |
North Park Pharmacy Type: Community/Retail Pharmacy Location: 7924 N 2nd St, Machesney Park, Illinois 61115 Phone: (815) 633-3431 |